Biomarkers in the Management of Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 198
Editor
Interests: lung cancer; biomarker
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer remains a formidable challenge in oncology, characterized by its diverse subtypes and often aggressive nature. The intricate landscape of lung malignancies, encompassing non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and various histological subtypes, underscores the need for precise diagnostic and therapeutic strategies. Despite advancements in treatment modalities, the prognosis for many lung cancer patients remains poor, necessitating innovative approaches to early detection and tailored interventions.
In recent years, the role of biomarkers has emerged as a critical frontier in the pursuit of more effective lung cancer management. Biomarkers, ranging from genetic mutations and expression profiles to circulating molecules, hold promise in revolutionizing both diagnostic precision and treatment outcomes. This Special Issue of the journal Cancers will delve into the evolving landscape of biomarker research in lung cancer and will shed light on recent breakthroughs and future directions in this dynamic field.
The advent of targeted therapies has redefined the treatment paradigm for certain subsets of lung cancer, with actionable mutations such as EGFR, ALK, and ROS1 paving the way for personalized medicine. The exploration of novel biomarkers, both predictive and prognostic, is expanding the repertoire of precision therapies. Additionally, immune checkpoint inhibitors have ushered in a new era in the immunotherapy landscape for lung cancer, offering unprecedented responses in a subset of patients.
However, challenges persist, particularly in the context of identifying biomarkers that transcend histological boundaries and predicting treatment responses in the heterogeneous landscape of lung cancer. The search for reliable biomarkers for early detection and monitoring of treatment responses is a focal point of ongoing research.
In this collection of articles, we present an overview of the current state of biomarker research in lung cancer, exploring the significance of emerging markers such as tumor mutational burden, PD-L1 expression, and liquid-biopsy-based approaches. As we navigate the complex terrain of lung cancer biomarkers, the articles within this Special Issue will provide valuable insights into the ongoing efforts to unravel the intricacies of this challenging disease. From predictive markers guiding targeted therapies to the dynamic landscape of immunotherapy, we invite readers to explore the forefront of biomarker-driven precision medicine in lung cancer.
Prof. Dr. Ole Hilberg
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- biomarker
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
